SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway
Although the clinical outcomes of diffuse large B‐cell lymphoma (DLBCL) have improved in the immunochemotherapy era, approximately one‐third of patients develop intractable disease. To improve clinical outcomes for these patients, it is important to identify those with poor prognosis prior to initia...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley and Sons Inc.
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021043/ |